Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
Gastric Cancer. 2021 Jul;24(4):844-857. doi: 10.1007/s10120-021-01163-y. Epub 2021 Feb 18.
Inactivation of TP53, a tumor suppressor gene, is associated with the development of several malignancies, including gastric cancer (GC). The present study aimed to evaluate the correlation between the overexpression of p53 and survival in different Lauren-type GCs.
From May 2003 to December 2019, 3608 GC patients treated endoscopically or surgically at the Seoul National University Bundang Hospital were enrolled for the study. Immunohistochemical staining for p53 was performed on all endoscopic and surgical gastric specimens. Clinicopathologic characteristics with Lauren classification, survival rate, and cancer recurrence were analyzed according to p53 overexpression.
Among 3608 GC patients, p53 overexpression was seen in 1334 patients (37%). p53 overexpression was associated with lower depth of invasion (P = 0.026) and Early gastric cancer (P = 0.044) in intestinal-type GC, and with advanced TNM stage (P < 0.001) and Advanced gastric cancer (P < 0.001) in diffuse-type GC. The overall survival (OS) and GC-specific survival (GCSS) were significantly lower in p53 overexpression positive patients. This significance was more pronounced and enhanced in the diffuse-type GC and was absent in the intestinal-type GC. In multivariate analyses, p53 overexpression was associated with poor OS in both subtypes of GC and cancer recurrence in diffuse-type GC. (OS in intestinal-type: adjusted hazard ratio [aHR] = 1.423, P = 0.022; OS in diffuse-type: aHR = 1.401 P = 0.035; cancer recurrence in diffuse-type: aHR = 1.502, P = 0.039).
p53 overexpression was associated with poor prognosis in GC, especially in diffuse-type. In addition, p53 overexpression was associated with early stage disease in intestinal-type GC and with advanced stage disease in diffuse-type GC.
肿瘤抑制基因 TP53 的失活与包括胃癌(GC)在内的多种恶性肿瘤的发展有关。本研究旨在评估不同 Lauren 型 GC 中 p53 过表达与生存的相关性。
本研究纳入了 2003 年 5 月至 2019 年 12 月期间在首尔国立大学盆唐医院接受内镜或手术治疗的 3608 例 GC 患者。对所有内镜和手术胃标本进行 p53 免疫组织化学染色。根据 p53 过表达情况分析临床病理特征、生存率和癌症复发情况。
在 3608 例 GC 患者中,1334 例(37%)存在 p53 过表达。p53 过表达与肠型 GC 的浸润深度较浅(P=0.026)和早期胃癌(P=0.044)有关,与弥漫型 GC 的较晚 TNM 分期(P<0.001)和晚期胃癌(P<0.001)有关。p53 过表达阳性患者的总生存期(OS)和 GC 特异性生存期(GCSS)显著降低。这种显著性在弥漫型 GC 中更为显著和增强,而在肠型 GC 中则不存在。多因素分析显示,p53 过表达与两种 GC 亚型的 OS 不良和弥漫型 GC 的癌症复发有关。(肠型:调整后的危险比[aHR]=1.423,P=0.022;弥漫型:aHR=1.401,P=0.035;弥漫型:aHR=1.502,P=0.039)。
p53 过表达与 GC 的预后不良有关,尤其是弥漫型。此外,p53 过表达与肠型 GC 的早期疾病有关,与弥漫型 GC 的晚期疾病有关。